Skip to main content
Premium Trial:

Request an Annual Quote

Venter Center Breaks Up TIGR and TCAG Into 10 Research Units, Shuffles Brass

NEW YORK (GenomeWeb News) — The J. Craig Venter Institute has reorganized the Institute for Genomic Research and the Center for the Advancement of Genomics into a pack of more tightly focused units, the institute said yesterday.  
 
The JCVI, with facilities in Rockville, Md., and La Jolla, Calif., will now consist of 10 distinct research groups: Genomic Medicine, Infectious Disease, Synthetic Biology & Bioenergy, Plant Genomics, Microbial & Environmental Genomics, Pathogen Functional Genomics, Applied Bioinformatics, Research Informatics, Software Engineering, and a Policy Center.
 
The institute added that its genomic sequencing arm “remains a cornerstone” of the JCVI, and that Yu-Hui Rogers will continue to lead it.
 
Craig Venter will remain president and chairman of the institute, and Robert Strausberg, who had been president of the TCAG division, has been named deputy director.
 
Eric Eisenstadt, former vice president for research of TIGR, has been named deputy vice president for research.
 
The restructuring comes around three weeks after the JCVI disclosed that Claire Fraser-Liggett has resigned as president of TIGR, and around six months since Venter consolidated TIGR, the JCVI, and the J. Craig Venter Science Foundation into a single organization, the JCVI.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.